Tracking the Fake Malaria Drug Threat (Asia)
This article was originally published in PharmAsia News
Executive Summary
People living in tropical regions in Cambodia, Laos, Vietnam, and Burma have high incident rates of malaria, but today one of the biggest growing threats they face is the prevalence of fake and fraudulent anti-malaria drugs. A university team from Oxford University, Bangkok-based Mahidol University, and the Wellcome Trust have started studying incidents of fake antimalarial drugs. Professor Nick Day reports from Cambodia that "in some areas 30-50 percent, or even more than 50 percent of drugs you buy randomly from pharmacies are actually fake. They contain no active anti-malarial ingredient." Some of these drugs contain starch, some paracetamol, and some just enough anti-malarial artemisinin substance to pass testing. Fake anti-malarial medicine with a small amounts of a legitimate active ingredient could spark drug resistance in malarial strains, and so are even more dangerous than purely fake drugs. Africa today has around 90 percent of the world's cases of malaria, and a rise in fake drug imports into Africa would create a health crisis, says Day. Interpol senior investigator John Newton says that in South-East Asia most often it is ethnic Chinese who are involved in organizing trans-national fake anti-malaria drug rings. World Health Organization official Dr. Henk Bekedam says China's government has begun increasing efforts to crack down on fake pharmaceuticals being made in China, a trend many experts welcome and want to see more of. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.